Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1b/2a Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-RDH12 Administered in Participants With Leber Congenital Amaurosis With Autosomal-Recessive Retinol Dehydrogenase 12 Mutations

This study is an early-stage clinical trial (Phase 1b/2a) testing a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by m…

Leber Congenital AmaurosisLeber Congenital Amaurosis (LCA)

Estimated

~$10 – $8,750

Opus Genetics, IncNCT07681778